Pharma & Healthcare
Global Radioligand Therapy Drugs for Cancer Market Research Report 2026
- Jan 17, 26
- ID: 687219
- Pages: 120
- Figures: 123
- Views: 10
This report delivers a comprehensive overview of the global Radioligand Therapy Drugs for Cancer market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Radioligand Therapy Drugs for Cancer. The Radioligand Therapy Drugs for Cancer market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Radioligand Therapy Drugs for Cancer market comprehensively. Regional market sizes by Type, by Application, by Targeted Ligands, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Radioligand Therapy Drugs for Cancer manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Novartis
Bayer
Progenics (Lantheus)
Acrotech Biopharma Inc
BMS
AstraZeneca
Eli Lilly
Convergent Therapeutics
Grand Pharmaceutical
Bivision Pharmaceuticals
Jiangsu Hengrui
Segment by Type
Lutetium 177
Radium 223
Acetium 225
Others
Segment by Targeted Ligands
by Peptides
Small Molecules
Antibodies
Others
Segment by Radionuclides
β-emitters
α-emitters
Others
by Application
Prostate Cancer
Liver Cancer
Breast Cancer
Lung Cancer
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Targeted Ligands, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Radioligand Therapy Drugs for Cancer manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Radioligand Therapy Drugs for Cancer sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
The report segments the global Radioligand Therapy Drugs for Cancer market comprehensively. Regional market sizes by Type, by Application, by Targeted Ligands, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Radioligand Therapy Drugs for Cancer manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Novartis
Bayer
Progenics (Lantheus)
Acrotech Biopharma Inc
BMS
AstraZeneca
Eli Lilly
Convergent Therapeutics
Grand Pharmaceutical
Bivision Pharmaceuticals
Jiangsu Hengrui
Segment by Type
Lutetium 177
Radium 223
Acetium 225
Others
Segment by Targeted Ligands
by Peptides
Small Molecules
Antibodies
Others
Segment by Radionuclides
β-emitters
α-emitters
Others
by Application
Prostate Cancer
Liver Cancer
Breast Cancer
Lung Cancer
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Targeted Ligands, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Radioligand Therapy Drugs for Cancer manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Radioligand Therapy Drugs for Cancer sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
1 Radioligand Therapy Drugs for Cancer Market Overview
1.1 Product Definition
1.2 Radioligand Therapy Drugs for Cancer by Type
1.2.1 Global Radioligand Therapy Drugs for Cancer Market Value by Type: 2025 vs 2032
1.2.2 Lutetium 177
1.2.3 Radium 223
1.2.4 Acetium 225
1.2.5 Others
1.3 Radioligand Therapy Drugs for Cancer by Targeted Ligands
1.3.1 Global Radioligand Therapy Drugs for Cancer Market Value by Targeted Ligands: 2025 vs 2032
1.3.2 by Peptides
1.3.3 Small Molecules
1.3.4 Antibodies
1.3.5 Others
1.4 Radioligand Therapy Drugs for Cancer by Radionuclides
1.4.1 Global Radioligand Therapy Drugs for Cancer Market Value by Radionuclides: 2025 vs 2032
1.4.2 β-emitters
1.4.3 α-emitters
1.4.4 Others
1.5 Radioligand Therapy Drugs for Cancer by Application
1.5.1 Global Radioligand Therapy Drugs for Cancer Market Value by Application: 2025 vs 2032
1.5.2 Prostate Cancer
1.5.3 Liver Cancer
1.5.4 Breast Cancer
1.5.5 Lung Cancer
1.5.6 Others
1.6 Global Radioligand Therapy Drugs for Cancer Market Size Estimates and Forecasts
1.6.1 Global Radioligand Therapy Drugs for Cancer Revenue 2021–2032
1.6.2 Global Radioligand Therapy Drugs for Cancer Sales 2021–2032
1.6.3 Global Radioligand Therapy Drugs for Cancer Market Average Price (2021–2032)
1.7 Assumptions and Limitations
2 Radioligand Therapy Drugs for Cancer Market Competition by Manufacturers
2.1 Global Radioligand Therapy Drugs for Cancer Sales Market Share by Manufacturers (2021–2026)
2.2 Global Radioligand Therapy Drugs for Cancer Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Radioligand Therapy Drugs for Cancer Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Radioligand Therapy Drugs for Cancer, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Radioligand Therapy Drugs for Cancer, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Radioligand Therapy Drugs for Cancer, Product Types and Applications
2.7 Global Key Manufacturers of Radioligand Therapy Drugs for Cancer, Date of Entry into the Industry
2.8 Global Radioligand Therapy Drugs for Cancer Market Competitive Situation and Trends
2.8.1 Global Radioligand Therapy Drugs for Cancer Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Radioligand Therapy Drugs for Cancer Players Market Share by Revenue
2.8.3 Global Radioligand Therapy Drugs for Cancer Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Radioligand Therapy Drugs for Cancer Market Scenario by Region
3.1 Global Radioligand Therapy Drugs for Cancer Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Radioligand Therapy Drugs for Cancer Sales by Region: 2021–2032
3.2.1 Global Radioligand Therapy Drugs for Cancer Sales by Region: 2021–2026
3.2.2 Global Radioligand Therapy Drugs for Cancer Sales by Region: 2027–2032
3.3 Global Radioligand Therapy Drugs for Cancer Revenue by Region: 2021–2032
3.3.1 Global Radioligand Therapy Drugs for Cancer Revenue by Region: 2021–2026
3.3.2 Global Radioligand Therapy Drugs for Cancer Revenue by Region: 2027–2032
3.4 North America Radioligand Therapy Drugs for Cancer Market Facts & Figures by Country
3.4.1 North America Radioligand Therapy Drugs for Cancer Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Radioligand Therapy Drugs for Cancer Sales by Country (2021–2032)
3.4.3 North America Radioligand Therapy Drugs for Cancer Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Radioligand Therapy Drugs for Cancer Market Facts & Figures by Country
3.5.1 Europe Radioligand Therapy Drugs for Cancer Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Radioligand Therapy Drugs for Cancer Sales by Country (2021–2032)
3.5.3 Europe Radioligand Therapy Drugs for Cancer Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Radioligand Therapy Drugs for Cancer Market Facts & Figures by Region
3.6.1 Asia Pacific Radioligand Therapy Drugs for Cancer Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Radioligand Therapy Drugs for Cancer Sales by Region (2021–2032)
3.6.3 Asia Pacific Radioligand Therapy Drugs for Cancer Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Radioligand Therapy Drugs for Cancer Market Facts & Figures by Country
3.7.1 Latin America Radioligand Therapy Drugs for Cancer Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Radioligand Therapy Drugs for Cancer Sales by Country (2021–2032)
3.7.3 Latin America Radioligand Therapy Drugs for Cancer Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Radioligand Therapy Drugs for Cancer Market Facts & Figures by Country
3.8.1 Middle East and Africa Radioligand Therapy Drugs for Cancer Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Radioligand Therapy Drugs for Cancer Sales by Country (2021–2032)
3.8.3 Middle East and Africa Radioligand Therapy Drugs for Cancer Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Radioligand Therapy Drugs for Cancer Sales by Type (2021–2032)
4.1.1 Global Radioligand Therapy Drugs for Cancer Sales by Type (2021–2026)
4.1.2 Global Radioligand Therapy Drugs for Cancer Sales by Type (2027–2032)
4.1.3 Global Radioligand Therapy Drugs for Cancer Sales Market Share by Type (2021–2032)
4.2 Global Radioligand Therapy Drugs for Cancer Revenue by Type (2021–2032)
4.2.1 Global Radioligand Therapy Drugs for Cancer Revenue by Type (2021–2026)
4.2.2 Global Radioligand Therapy Drugs for Cancer Revenue by Type (2027–2032)
4.2.3 Global Radioligand Therapy Drugs for Cancer Revenue Market Share by Type (2021–2032)
4.3 Global Radioligand Therapy Drugs for Cancer Price by Type (2021–2032)
5 Segment by Application
5.1 Global Radioligand Therapy Drugs for Cancer Sales by Application (2021–2032)
5.1.1 Global Radioligand Therapy Drugs for Cancer Sales by Application (2021–2026)
5.1.2 Global Radioligand Therapy Drugs for Cancer Sales by Application (2027–2032)
5.1.3 Global Radioligand Therapy Drugs for Cancer Sales Market Share by Application (2021–2032)
5.2 Global Radioligand Therapy Drugs for Cancer Revenue by Application (2021–2032)
5.2.1 Global Radioligand Therapy Drugs for Cancer Revenue by Application (2021–2026)
5.2.2 Global Radioligand Therapy Drugs for Cancer Revenue by Application (2027–2032)
5.2.3 Global Radioligand Therapy Drugs for Cancer Revenue Market Share by Application (2021–2032)
5.3 Global Radioligand Therapy Drugs for Cancer Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Company Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Radioligand Therapy Drugs for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Novartis Radioligand Therapy Drugs for Cancer Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Bayer
6.2.1 Bayer Company Information
6.2.2 Bayer Description and Business Overview
6.2.3 Bayer Radioligand Therapy Drugs for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Bayer Radioligand Therapy Drugs for Cancer Product Portfolio
6.2.5 Bayer Recent Developments/Updates
6.3 Progenics (Lantheus)
6.3.1 Progenics (Lantheus) Company Information
6.3.2 Progenics (Lantheus) Description and Business Overview
6.3.3 Progenics (Lantheus) Radioligand Therapy Drugs for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Progenics (Lantheus) Radioligand Therapy Drugs for Cancer Product Portfolio
6.3.5 Progenics (Lantheus) Recent Developments/Updates
6.4 Acrotech Biopharma Inc
6.4.1 Acrotech Biopharma Inc Company Information
6.4.2 Acrotech Biopharma Inc Description and Business Overview
6.4.3 Acrotech Biopharma Inc Radioligand Therapy Drugs for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Acrotech Biopharma Inc Radioligand Therapy Drugs for Cancer Product Portfolio
6.4.5 Acrotech Biopharma Inc Recent Developments/Updates
6.5 BMS
6.5.1 BMS Company Information
6.5.2 BMS Description and Business Overview
6.5.3 BMS Radioligand Therapy Drugs for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 BMS Radioligand Therapy Drugs for Cancer Product Portfolio
6.5.5 BMS Recent Developments/Updates
6.6 AstraZeneca
6.6.1 AstraZeneca Company Information
6.6.2 AstraZeneca Description and Business Overview
6.6.3 AstraZeneca Radioligand Therapy Drugs for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 AstraZeneca Radioligand Therapy Drugs for Cancer Product Portfolio
6.6.5 AstraZeneca Recent Developments/Updates
6.7 Eli Lilly
6.7.1 Eli Lilly Company Information
6.7.2 Eli Lilly Description and Business Overview
6.7.3 Eli Lilly Radioligand Therapy Drugs for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Eli Lilly Radioligand Therapy Drugs for Cancer Product Portfolio
6.7.5 Eli Lilly Recent Developments/Updates
6.8 Convergent Therapeutics
6.8.1 Convergent Therapeutics Company Information
6.8.2 Convergent Therapeutics Description and Business Overview
6.8.3 Convergent Therapeutics Radioligand Therapy Drugs for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Convergent Therapeutics Radioligand Therapy Drugs for Cancer Product Portfolio
6.8.5 Convergent Therapeutics Recent Developments/Updates
6.9 Grand Pharmaceutical
6.9.1 Grand Pharmaceutical Company Information
6.9.2 Grand Pharmaceutical Description and Business Overview
6.9.3 Grand Pharmaceutical Radioligand Therapy Drugs for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Grand Pharmaceutical Radioligand Therapy Drugs for Cancer Product Portfolio
6.9.5 Grand Pharmaceutical Recent Developments/Updates
6.10 Bivision Pharmaceuticals
6.10.1 Bivision Pharmaceuticals Company Information
6.10.2 Bivision Pharmaceuticals Description and Business Overview
6.10.3 Bivision Pharmaceuticals Radioligand Therapy Drugs for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Bivision Pharmaceuticals Radioligand Therapy Drugs for Cancer Product Portfolio
6.10.5 Bivision Pharmaceuticals Recent Developments/Updates
6.11 Jiangsu Hengrui
6.11.1 Jiangsu Hengrui Company Information
6.11.2 Jiangsu Hengrui Description and Business Overview
6.11.3 Jiangsu Hengrui Radioligand Therapy Drugs for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Jiangsu Hengrui Radioligand Therapy Drugs for Cancer Product Portfolio
6.11.5 Jiangsu Hengrui Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Radioligand Therapy Drugs for Cancer Industry Chain Analysis
7.2 Radioligand Therapy Drugs for Cancer Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Radioligand Therapy Drugs for Cancer Production Mode & Process Analysis
7.4 Radioligand Therapy Drugs for Cancer Sales and Marketing
7.4.1 Radioligand Therapy Drugs for Cancer Sales Channels
7.4.2 Radioligand Therapy Drugs for Cancer Distributors
7.5 Radioligand Therapy Drugs for Cancer Customer Analysis
8 Radioligand Therapy Drugs for Cancer Market Dynamics
8.1 Radioligand Therapy Drugs for Cancer Industry Trends
8.2 Radioligand Therapy Drugs for Cancer Market Drivers
8.3 Radioligand Therapy Drugs for Cancer Market Challenges
8.4 Radioligand Therapy Drugs for Cancer Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Radioligand Therapy Drugs for Cancer by Type
1.2.1 Global Radioligand Therapy Drugs for Cancer Market Value by Type: 2025 vs 2032
1.2.2 Lutetium 177
1.2.3 Radium 223
1.2.4 Acetium 225
1.2.5 Others
1.3 Radioligand Therapy Drugs for Cancer by Targeted Ligands
1.3.1 Global Radioligand Therapy Drugs for Cancer Market Value by Targeted Ligands: 2025 vs 2032
1.3.2 by Peptides
1.3.3 Small Molecules
1.3.4 Antibodies
1.3.5 Others
1.4 Radioligand Therapy Drugs for Cancer by Radionuclides
1.4.1 Global Radioligand Therapy Drugs for Cancer Market Value by Radionuclides: 2025 vs 2032
1.4.2 β-emitters
1.4.3 α-emitters
1.4.4 Others
1.5 Radioligand Therapy Drugs for Cancer by Application
1.5.1 Global Radioligand Therapy Drugs for Cancer Market Value by Application: 2025 vs 2032
1.5.2 Prostate Cancer
1.5.3 Liver Cancer
1.5.4 Breast Cancer
1.5.5 Lung Cancer
1.5.6 Others
1.6 Global Radioligand Therapy Drugs for Cancer Market Size Estimates and Forecasts
1.6.1 Global Radioligand Therapy Drugs for Cancer Revenue 2021–2032
1.6.2 Global Radioligand Therapy Drugs for Cancer Sales 2021–2032
1.6.3 Global Radioligand Therapy Drugs for Cancer Market Average Price (2021–2032)
1.7 Assumptions and Limitations
2 Radioligand Therapy Drugs for Cancer Market Competition by Manufacturers
2.1 Global Radioligand Therapy Drugs for Cancer Sales Market Share by Manufacturers (2021–2026)
2.2 Global Radioligand Therapy Drugs for Cancer Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Radioligand Therapy Drugs for Cancer Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Radioligand Therapy Drugs for Cancer, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Radioligand Therapy Drugs for Cancer, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Radioligand Therapy Drugs for Cancer, Product Types and Applications
2.7 Global Key Manufacturers of Radioligand Therapy Drugs for Cancer, Date of Entry into the Industry
2.8 Global Radioligand Therapy Drugs for Cancer Market Competitive Situation and Trends
2.8.1 Global Radioligand Therapy Drugs for Cancer Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Radioligand Therapy Drugs for Cancer Players Market Share by Revenue
2.8.3 Global Radioligand Therapy Drugs for Cancer Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Radioligand Therapy Drugs for Cancer Market Scenario by Region
3.1 Global Radioligand Therapy Drugs for Cancer Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Radioligand Therapy Drugs for Cancer Sales by Region: 2021–2032
3.2.1 Global Radioligand Therapy Drugs for Cancer Sales by Region: 2021–2026
3.2.2 Global Radioligand Therapy Drugs for Cancer Sales by Region: 2027–2032
3.3 Global Radioligand Therapy Drugs for Cancer Revenue by Region: 2021–2032
3.3.1 Global Radioligand Therapy Drugs for Cancer Revenue by Region: 2021–2026
3.3.2 Global Radioligand Therapy Drugs for Cancer Revenue by Region: 2027–2032
3.4 North America Radioligand Therapy Drugs for Cancer Market Facts & Figures by Country
3.4.1 North America Radioligand Therapy Drugs for Cancer Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Radioligand Therapy Drugs for Cancer Sales by Country (2021–2032)
3.4.3 North America Radioligand Therapy Drugs for Cancer Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Radioligand Therapy Drugs for Cancer Market Facts & Figures by Country
3.5.1 Europe Radioligand Therapy Drugs for Cancer Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Radioligand Therapy Drugs for Cancer Sales by Country (2021–2032)
3.5.3 Europe Radioligand Therapy Drugs for Cancer Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Radioligand Therapy Drugs for Cancer Market Facts & Figures by Region
3.6.1 Asia Pacific Radioligand Therapy Drugs for Cancer Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Radioligand Therapy Drugs for Cancer Sales by Region (2021–2032)
3.6.3 Asia Pacific Radioligand Therapy Drugs for Cancer Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Radioligand Therapy Drugs for Cancer Market Facts & Figures by Country
3.7.1 Latin America Radioligand Therapy Drugs for Cancer Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Radioligand Therapy Drugs for Cancer Sales by Country (2021–2032)
3.7.3 Latin America Radioligand Therapy Drugs for Cancer Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Radioligand Therapy Drugs for Cancer Market Facts & Figures by Country
3.8.1 Middle East and Africa Radioligand Therapy Drugs for Cancer Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Radioligand Therapy Drugs for Cancer Sales by Country (2021–2032)
3.8.3 Middle East and Africa Radioligand Therapy Drugs for Cancer Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Radioligand Therapy Drugs for Cancer Sales by Type (2021–2032)
4.1.1 Global Radioligand Therapy Drugs for Cancer Sales by Type (2021–2026)
4.1.2 Global Radioligand Therapy Drugs for Cancer Sales by Type (2027–2032)
4.1.3 Global Radioligand Therapy Drugs for Cancer Sales Market Share by Type (2021–2032)
4.2 Global Radioligand Therapy Drugs for Cancer Revenue by Type (2021–2032)
4.2.1 Global Radioligand Therapy Drugs for Cancer Revenue by Type (2021–2026)
4.2.2 Global Radioligand Therapy Drugs for Cancer Revenue by Type (2027–2032)
4.2.3 Global Radioligand Therapy Drugs for Cancer Revenue Market Share by Type (2021–2032)
4.3 Global Radioligand Therapy Drugs for Cancer Price by Type (2021–2032)
5 Segment by Application
5.1 Global Radioligand Therapy Drugs for Cancer Sales by Application (2021–2032)
5.1.1 Global Radioligand Therapy Drugs for Cancer Sales by Application (2021–2026)
5.1.2 Global Radioligand Therapy Drugs for Cancer Sales by Application (2027–2032)
5.1.3 Global Radioligand Therapy Drugs for Cancer Sales Market Share by Application (2021–2032)
5.2 Global Radioligand Therapy Drugs for Cancer Revenue by Application (2021–2032)
5.2.1 Global Radioligand Therapy Drugs for Cancer Revenue by Application (2021–2026)
5.2.2 Global Radioligand Therapy Drugs for Cancer Revenue by Application (2027–2032)
5.2.3 Global Radioligand Therapy Drugs for Cancer Revenue Market Share by Application (2021–2032)
5.3 Global Radioligand Therapy Drugs for Cancer Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Company Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Radioligand Therapy Drugs for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Novartis Radioligand Therapy Drugs for Cancer Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Bayer
6.2.1 Bayer Company Information
6.2.2 Bayer Description and Business Overview
6.2.3 Bayer Radioligand Therapy Drugs for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Bayer Radioligand Therapy Drugs for Cancer Product Portfolio
6.2.5 Bayer Recent Developments/Updates
6.3 Progenics (Lantheus)
6.3.1 Progenics (Lantheus) Company Information
6.3.2 Progenics (Lantheus) Description and Business Overview
6.3.3 Progenics (Lantheus) Radioligand Therapy Drugs for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Progenics (Lantheus) Radioligand Therapy Drugs for Cancer Product Portfolio
6.3.5 Progenics (Lantheus) Recent Developments/Updates
6.4 Acrotech Biopharma Inc
6.4.1 Acrotech Biopharma Inc Company Information
6.4.2 Acrotech Biopharma Inc Description and Business Overview
6.4.3 Acrotech Biopharma Inc Radioligand Therapy Drugs for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Acrotech Biopharma Inc Radioligand Therapy Drugs for Cancer Product Portfolio
6.4.5 Acrotech Biopharma Inc Recent Developments/Updates
6.5 BMS
6.5.1 BMS Company Information
6.5.2 BMS Description and Business Overview
6.5.3 BMS Radioligand Therapy Drugs for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 BMS Radioligand Therapy Drugs for Cancer Product Portfolio
6.5.5 BMS Recent Developments/Updates
6.6 AstraZeneca
6.6.1 AstraZeneca Company Information
6.6.2 AstraZeneca Description and Business Overview
6.6.3 AstraZeneca Radioligand Therapy Drugs for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 AstraZeneca Radioligand Therapy Drugs for Cancer Product Portfolio
6.6.5 AstraZeneca Recent Developments/Updates
6.7 Eli Lilly
6.7.1 Eli Lilly Company Information
6.7.2 Eli Lilly Description and Business Overview
6.7.3 Eli Lilly Radioligand Therapy Drugs for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Eli Lilly Radioligand Therapy Drugs for Cancer Product Portfolio
6.7.5 Eli Lilly Recent Developments/Updates
6.8 Convergent Therapeutics
6.8.1 Convergent Therapeutics Company Information
6.8.2 Convergent Therapeutics Description and Business Overview
6.8.3 Convergent Therapeutics Radioligand Therapy Drugs for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Convergent Therapeutics Radioligand Therapy Drugs for Cancer Product Portfolio
6.8.5 Convergent Therapeutics Recent Developments/Updates
6.9 Grand Pharmaceutical
6.9.1 Grand Pharmaceutical Company Information
6.9.2 Grand Pharmaceutical Description and Business Overview
6.9.3 Grand Pharmaceutical Radioligand Therapy Drugs for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Grand Pharmaceutical Radioligand Therapy Drugs for Cancer Product Portfolio
6.9.5 Grand Pharmaceutical Recent Developments/Updates
6.10 Bivision Pharmaceuticals
6.10.1 Bivision Pharmaceuticals Company Information
6.10.2 Bivision Pharmaceuticals Description and Business Overview
6.10.3 Bivision Pharmaceuticals Radioligand Therapy Drugs for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Bivision Pharmaceuticals Radioligand Therapy Drugs for Cancer Product Portfolio
6.10.5 Bivision Pharmaceuticals Recent Developments/Updates
6.11 Jiangsu Hengrui
6.11.1 Jiangsu Hengrui Company Information
6.11.2 Jiangsu Hengrui Description and Business Overview
6.11.3 Jiangsu Hengrui Radioligand Therapy Drugs for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Jiangsu Hengrui Radioligand Therapy Drugs for Cancer Product Portfolio
6.11.5 Jiangsu Hengrui Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Radioligand Therapy Drugs for Cancer Industry Chain Analysis
7.2 Radioligand Therapy Drugs for Cancer Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Radioligand Therapy Drugs for Cancer Production Mode & Process Analysis
7.4 Radioligand Therapy Drugs for Cancer Sales and Marketing
7.4.1 Radioligand Therapy Drugs for Cancer Sales Channels
7.4.2 Radioligand Therapy Drugs for Cancer Distributors
7.5 Radioligand Therapy Drugs for Cancer Customer Analysis
8 Radioligand Therapy Drugs for Cancer Market Dynamics
8.1 Radioligand Therapy Drugs for Cancer Industry Trends
8.2 Radioligand Therapy Drugs for Cancer Market Drivers
8.3 Radioligand Therapy Drugs for Cancer Market Challenges
8.4 Radioligand Therapy Drugs for Cancer Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Radioligand Therapy Drugs for Cancer Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Radioligand Therapy Drugs for Cancer Market Value by Targeted Ligands (US$ Million), 2025 vs 2032
Table 3. Global Radioligand Therapy Drugs for Cancer Market Value by Radionuclides (US$ Million), 2025 vs 2032
Table 4. Global Radioligand Therapy Drugs for Cancer Market Value by Application (US$ Million), 2025 vs 2032
Table 5. Global Radioligand Therapy Drugs for Cancer Market Competitive Situation by Manufacturers in 2025
Table 6. Global Radioligand Therapy Drugs for Cancer Sales (K Units) of Key Manufacturers (2021–2026)
Table 7. Global Radioligand Therapy Drugs for Cancer Sales Market Share by Manufacturers (2021–2026)
Table 8. Global Radioligand Therapy Drugs for Cancer Revenue (US$ Million) by Manufacturers (2021–2026)
Table 9. Global Radioligand Therapy Drugs for Cancer Revenue Share by Manufacturers (2021–2026)
Table 10. Global Market Radioligand Therapy Drugs for Cancer Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 11. Global Key Players of Radioligand Therapy Drugs for Cancer, Industry Ranking, 2023 vs 2024 vs 2025
Table 12. Global Key Manufacturers of Radioligand Therapy Drugs for Cancer, Manufacturing Sites and Headquarters
Table 13. Global Key Manufacturers of Radioligand Therapy Drugs for Cancer, Product Types and Applications
Table 14. Global Key Manufacturers of Radioligand Therapy Drugs for Cancer, Date of Entry into the Industry
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Radioligand Therapy Drugs for Cancer Companies by Tier (Tier 1, Tier 2, Tier 3), based on Radioligand Therapy Drugs for Cancer Revenue, 2025
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 18. Global Radioligand Therapy Drugs for Cancer Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 19. Global Radioligand Therapy Drugs for Cancer Sales by Region (K Units), 2021–2026
Table 20. Global Radioligand Therapy Drugs for Cancer Sales Market Share by Region (2021–2026)
Table 21. Global Radioligand Therapy Drugs for Cancer Sales by Region (K Units), 2027–2032
Table 22. Global Radioligand Therapy Drugs for Cancer Sales Market Share by Region (2027–2032)
Table 23. Global Radioligand Therapy Drugs for Cancer Revenue by Region (US$ Million), 2021–2026
Table 24. Global Radioligand Therapy Drugs for Cancer Revenue Market Share by Region (2021–2026)
Table 25. Global Radioligand Therapy Drugs for Cancer Revenue by Region (US$ Million), 2027–2032
Table 26. Global Radioligand Therapy Drugs for Cancer Revenue Market Share by Region (2027–2032)
Table 27. North America Radioligand Therapy Drugs for Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 28. North America Radioligand Therapy Drugs for Cancer Sales by Country (K Units), 2021–2026
Table 29. North America Radioligand Therapy Drugs for Cancer Sales by Country (K Units), 2027–2032
Table 30. North America Radioligand Therapy Drugs for Cancer Revenue by Country (US$ Million), 2021–2026
Table 31. North America Radioligand Therapy Drugs for Cancer Revenue by Country (US$ Million), 2027–2032
Table 32. Europe Radioligand Therapy Drugs for Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 33. Europe Radioligand Therapy Drugs for Cancer Sales by Country (K Units), 2021–2026
Table 34. Europe Radioligand Therapy Drugs for Cancer Sales by Country (K Units), 2027–2032
Table 35. Europe Radioligand Therapy Drugs for Cancer Revenue by Country (US$ Million), 2021–2026
Table 36. Europe Radioligand Therapy Drugs for Cancer Revenue by Country (US$ Million), 2027–2032
Table 37. Asia Pacific Radioligand Therapy Drugs for Cancer Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 38. Asia Pacific Radioligand Therapy Drugs for Cancer Sales by Region (K Units), 2021–2026
Table 39. Asia Pacific Radioligand Therapy Drugs for Cancer Sales by Region (K Units), 2027–2032
Table 40. Asia Pacific Radioligand Therapy Drugs for Cancer Revenue by Region (US$ Million), 2021–2026
Table 41. Asia Pacific Radioligand Therapy Drugs for Cancer Revenue by Region (US$ Million), 2027–2032
Table 42. Latin America Radioligand Therapy Drugs for Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 43. Latin America Radioligand Therapy Drugs for Cancer Sales by Country (K Units), 2021–2026
Table 44. Latin America Radioligand Therapy Drugs for Cancer Sales by Country (K Units), 2027–2032
Table 45. Latin America Radioligand Therapy Drugs for Cancer Revenue by Country (US$ Million), 2021–2026
Table 46. Latin America Radioligand Therapy Drugs for Cancer Revenue by Country (US$ Million), 2027–2032
Table 47. Middle East and Africa Radioligand Therapy Drugs for Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 48. Middle East and Africa Radioligand Therapy Drugs for Cancer Sales by Country (K Units), 2021–2026
Table 49. Middle East and Africa Radioligand Therapy Drugs for Cancer Sales by Country (K Units), 2027–2032
Table 50. Middle East and Africa Radioligand Therapy Drugs for Cancer Revenue by Country (US$ Million), 2021–2026
Table 51. Middle East and Africa Radioligand Therapy Drugs for Cancer Revenue by Country (US$ Million), 2027–2032
Table 52. Global Radioligand Therapy Drugs for Cancer Sales (K Units) by Type (2021–2026)
Table 53. Global Radioligand Therapy Drugs for Cancer Sales (K Units) by Type (2027–2032)
Table 54. Global Radioligand Therapy Drugs for Cancer Sales Market Share by Type (2021–2026)
Table 55. Global Radioligand Therapy Drugs for Cancer Sales Market Share by Type (2027–2032)
Table 56. Global Radioligand Therapy Drugs for Cancer Revenue (US$ Million) by Type (2021–2026)
Table 57. Global Radioligand Therapy Drugs for Cancer Revenue (US$ Million) by Type (2027–2032)
Table 58. Global Radioligand Therapy Drugs for Cancer Revenue Market Share by Type (2021–2026)
Table 59. Global Radioligand Therapy Drugs for Cancer Revenue Market Share by Type (2027–2032)
Table 60. Global Radioligand Therapy Drugs for Cancer Price (US$/Unit) by Type (2021–2026)
Table 61. Global Radioligand Therapy Drugs for Cancer Price (US$/Unit) by Type (2027–2032)
Table 62. Global Radioligand Therapy Drugs for Cancer Sales (K Units) by Application (2021–2026)
Table 63. Global Radioligand Therapy Drugs for Cancer Sales (K Units) by Application (2027–2032)
Table 64. Global Radioligand Therapy Drugs for Cancer Sales Market Share by Application (2021–2026)
Table 65. Global Radioligand Therapy Drugs for Cancer Sales Market Share by Application (2027–2032)
Table 66. Global Radioligand Therapy Drugs for Cancer Revenue (US$ Million) by Application (2021–2026)
Table 67. Global Radioligand Therapy Drugs for Cancer Revenue (US$ Million) by Application (2027–2032)
Table 68. Global Radioligand Therapy Drugs for Cancer Revenue Market Share by Application (2021–2026)
Table 69. Global Radioligand Therapy Drugs for Cancer Revenue Market Share by Application (2027–2032)
Table 70. Global Radioligand Therapy Drugs for Cancer Price (US$/Unit) by Application (2021–2026)
Table 71. Global Radioligand Therapy Drugs for Cancer Price (US$/Unit) by Application (2027–2032)
Table 72. Novartis Company Information
Table 73. Novartis Description and Business Overview
Table 74. Novartis Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 75. Novartis Radioligand Therapy Drugs for Cancer Product
Table 76. Novartis Recent Developments/Updates
Table 77. Bayer Company Information
Table 78. Bayer Description and Business Overview
Table 79. Bayer Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 80. Bayer Radioligand Therapy Drugs for Cancer Product
Table 81. Bayer Recent Developments/Updates
Table 82. Progenics (Lantheus) Company Information
Table 83. Progenics (Lantheus) Description and Business Overview
Table 84. Progenics (Lantheus) Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 85. Progenics (Lantheus) Radioligand Therapy Drugs for Cancer Product
Table 86. Progenics (Lantheus) Recent Developments/Updates
Table 87. Acrotech Biopharma Inc Company Information
Table 88. Acrotech Biopharma Inc Description and Business Overview
Table 89. Acrotech Biopharma Inc Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 90. Acrotech Biopharma Inc Radioligand Therapy Drugs for Cancer Product
Table 91. Acrotech Biopharma Inc Recent Developments/Updates
Table 92. BMS Company Information
Table 93. BMS Description and Business Overview
Table 94. BMS Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 95. BMS Radioligand Therapy Drugs for Cancer Product
Table 96. BMS Recent Developments/Updates
Table 97. AstraZeneca Company Information
Table 98. AstraZeneca Description and Business Overview
Table 99. AstraZeneca Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 100. AstraZeneca Radioligand Therapy Drugs for Cancer Product
Table 101. AstraZeneca Recent Developments/Updates
Table 102. Eli Lilly Company Information
Table 103. Eli Lilly Description and Business Overview
Table 104. Eli Lilly Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 105. Eli Lilly Radioligand Therapy Drugs for Cancer Product
Table 106. Eli Lilly Recent Developments/Updates
Table 107. Convergent Therapeutics Company Information
Table 108. Convergent Therapeutics Description and Business Overview
Table 109. Convergent Therapeutics Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 110. Convergent Therapeutics Radioligand Therapy Drugs for Cancer Product
Table 111. Convergent Therapeutics Recent Developments/Updates
Table 112. Grand Pharmaceutical Company Information
Table 113. Grand Pharmaceutical Description and Business Overview
Table 114. Grand Pharmaceutical Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 115. Grand Pharmaceutical Radioligand Therapy Drugs for Cancer Product
Table 116. Grand Pharmaceutical Recent Developments/Updates
Table 117. Bivision Pharmaceuticals Company Information
Table 118. Bivision Pharmaceuticals Description and Business Overview
Table 119. Bivision Pharmaceuticals Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 120. Bivision Pharmaceuticals Radioligand Therapy Drugs for Cancer Product
Table 121. Bivision Pharmaceuticals Recent Developments/Updates
Table 122. Jiangsu Hengrui Company Information
Table 123. Jiangsu Hengrui Description and Business Overview
Table 124. Jiangsu Hengrui Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 125. Jiangsu Hengrui Radioligand Therapy Drugs for Cancer Product
Table 126. Jiangsu Hengrui Recent Developments/Updates
Table 127. Key Raw Materials Lists
Table 128. Raw Materials Key Suppliers Lists
Table 129. Radioligand Therapy Drugs for Cancer Distributors List
Table 130. Radioligand Therapy Drugs for Cancer Customers List
Table 131. Radioligand Therapy Drugs for Cancer Market Trends
Table 132. Radioligand Therapy Drugs for Cancer Market Drivers
Table 133. Radioligand Therapy Drugs for Cancer Market Challenges
Table 134. Radioligand Therapy Drugs for Cancer Market Restraints
Table 135. Research Programs/Design for This Report
Table 136. Key Data Information from Secondary Sources
Table 137. Key Data Information from Primary Sources
Table 138. Authors List of This Report
List of Figures
Figure 1. Product Picture of Radioligand Therapy Drugs for Cancer
Figure 2. Global Radioligand Therapy Drugs for Cancer Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Radioligand Therapy Drugs for Cancer Market Share by Type: 2025 & 2032
Figure 4. Lutetium 177 Product Picture
Figure 5. Radium 223 Product Picture
Figure 6. Acetium 225 Product Picture
Figure 7. Others Product Picture
Figure 8. Global Radioligand Therapy Drugs for Cancer Market Value by Targeted Ligands (US$ Million), 2021–2032
Figure 9. Global Radioligand Therapy Drugs for Cancer Market Share by Targeted Ligands: 2025 vs 2032
Figure 10. by Peptides Product Picture
Figure 11. Small Molecules Product Picture
Figure 12. Antibodies Product Picture
Figure 13. Others Product Picture
Figure 14. Global Radioligand Therapy Drugs for Cancer Market Value by Radionuclides (US$ Million), 2021–2032
Figure 15. Global Radioligand Therapy Drugs for Cancer Market Share by Radionuclides: 2025 vs 2032
Figure 16. β-emitters Product Picture
Figure 17. α-emitters Product Picture
Figure 18. Others Product Picture
Figure 19. Global Radioligand Therapy Drugs for Cancer Market Value by Application (US$ Million), 2021–2032
Figure 20. Global Radioligand Therapy Drugs for Cancer Market Share by Application: 2025 & 2032
Figure 21. Prostate Cancer
Figure 22. Liver Cancer
Figure 23. Breast Cancer
Figure 24. Lung Cancer
Figure 25. Others
Figure 26. Global Radioligand Therapy Drugs for Cancer Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 27. Global Radioligand Therapy Drugs for Cancer Market Size (US$ Million), 2021–2032
Figure 28. Global Radioligand Therapy Drugs for Cancer Sales (K Units), 2021–2032
Figure 29. Global Radioligand Therapy Drugs for Cancer Average Price (US$/Unit), 2021–2032
Figure 30. Radioligand Therapy Drugs for Cancer Report Years Considered
Figure 31. Radioligand Therapy Drugs for Cancer Sales Share by Manufacturers in 2025
Figure 32. Global Radioligand Therapy Drugs for Cancer Revenue Share by Manufacturers in 2025
Figure 33. Top 5 and Top 10 Global Radioligand Therapy Drugs for Cancer Players: Market Share by Revenue in Radioligand Therapy Drugs for Cancer in 2025
Figure 34. Radioligand Therapy Drugs for Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 35. Global Radioligand Therapy Drugs for Cancer Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 36. North America Radioligand Therapy Drugs for Cancer Sales Market Share by Country (2021–2032)
Figure 37. North America Radioligand Therapy Drugs for Cancer Revenue Market Share by Country (2021–2032)
Figure 38. United States Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Canada Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Europe Radioligand Therapy Drugs for Cancer Sales Market Share by Country (2021–2032)
Figure 41. Europe Radioligand Therapy Drugs for Cancer Revenue Market Share by Country (2021–2032)
Figure 42. Germany Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. France Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. U.K. Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Italy Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Russia Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Asia Pacific Radioligand Therapy Drugs for Cancer Sales Market Share by Region (2021–2032)
Figure 48. Asia Pacific Radioligand Therapy Drugs for Cancer Revenue Market Share by Region (2021–2032)
Figure 49. China Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Japan Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. South Korea Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. India Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Australia Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. China Taiwan Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Southeast Asia Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. Latin America Radioligand Therapy Drugs for Cancer Sales Market Share by Country (2021–2032)
Figure 57. Latin America Radioligand Therapy Drugs for Cancer Revenue Market Share by Country (2021–2032)
Figure 58. Mexico Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 59. Brazil Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 60. Argentina Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 61. Colombia Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 62. Middle East and Africa Radioligand Therapy Drugs for Cancer Sales Market Share by Country (2021–2032)
Figure 63. Middle East and Africa Radioligand Therapy Drugs for Cancer Revenue Market Share by Country (2021–2032)
Figure 64. Turkey Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 65. Saudi Arabia Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 66. UAE Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 67. Global Sales Market Share of Radioligand Therapy Drugs for Cancer by Type (2021–2032)
Figure 68. Global Revenue Market Share of Radioligand Therapy Drugs for Cancer by Type (2021–2032)
Figure 69. Global Radioligand Therapy Drugs for Cancer Price (US$/Unit) by Type (2021–2032)
Figure 70. Global Sales Market Share of Radioligand Therapy Drugs for Cancer by Application (2021–2032)
Figure 71. Global Revenue Market Share of Radioligand Therapy Drugs for Cancer by Application (2021–2032)
Figure 72. Global Radioligand Therapy Drugs for Cancer Price (US$/Unit) by Application (2021–2032)
Figure 73. Radioligand Therapy Drugs for Cancer Value Chain
Figure 74. Channels of Distribution (Direct Vs Distribution)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed
Table 1. Global Radioligand Therapy Drugs for Cancer Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Radioligand Therapy Drugs for Cancer Market Value by Targeted Ligands (US$ Million), 2025 vs 2032
Table 3. Global Radioligand Therapy Drugs for Cancer Market Value by Radionuclides (US$ Million), 2025 vs 2032
Table 4. Global Radioligand Therapy Drugs for Cancer Market Value by Application (US$ Million), 2025 vs 2032
Table 5. Global Radioligand Therapy Drugs for Cancer Market Competitive Situation by Manufacturers in 2025
Table 6. Global Radioligand Therapy Drugs for Cancer Sales (K Units) of Key Manufacturers (2021–2026)
Table 7. Global Radioligand Therapy Drugs for Cancer Sales Market Share by Manufacturers (2021–2026)
Table 8. Global Radioligand Therapy Drugs for Cancer Revenue (US$ Million) by Manufacturers (2021–2026)
Table 9. Global Radioligand Therapy Drugs for Cancer Revenue Share by Manufacturers (2021–2026)
Table 10. Global Market Radioligand Therapy Drugs for Cancer Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 11. Global Key Players of Radioligand Therapy Drugs for Cancer, Industry Ranking, 2023 vs 2024 vs 2025
Table 12. Global Key Manufacturers of Radioligand Therapy Drugs for Cancer, Manufacturing Sites and Headquarters
Table 13. Global Key Manufacturers of Radioligand Therapy Drugs for Cancer, Product Types and Applications
Table 14. Global Key Manufacturers of Radioligand Therapy Drugs for Cancer, Date of Entry into the Industry
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Radioligand Therapy Drugs for Cancer Companies by Tier (Tier 1, Tier 2, Tier 3), based on Radioligand Therapy Drugs for Cancer Revenue, 2025
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 18. Global Radioligand Therapy Drugs for Cancer Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 19. Global Radioligand Therapy Drugs for Cancer Sales by Region (K Units), 2021–2026
Table 20. Global Radioligand Therapy Drugs for Cancer Sales Market Share by Region (2021–2026)
Table 21. Global Radioligand Therapy Drugs for Cancer Sales by Region (K Units), 2027–2032
Table 22. Global Radioligand Therapy Drugs for Cancer Sales Market Share by Region (2027–2032)
Table 23. Global Radioligand Therapy Drugs for Cancer Revenue by Region (US$ Million), 2021–2026
Table 24. Global Radioligand Therapy Drugs for Cancer Revenue Market Share by Region (2021–2026)
Table 25. Global Radioligand Therapy Drugs for Cancer Revenue by Region (US$ Million), 2027–2032
Table 26. Global Radioligand Therapy Drugs for Cancer Revenue Market Share by Region (2027–2032)
Table 27. North America Radioligand Therapy Drugs for Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 28. North America Radioligand Therapy Drugs for Cancer Sales by Country (K Units), 2021–2026
Table 29. North America Radioligand Therapy Drugs for Cancer Sales by Country (K Units), 2027–2032
Table 30. North America Radioligand Therapy Drugs for Cancer Revenue by Country (US$ Million), 2021–2026
Table 31. North America Radioligand Therapy Drugs for Cancer Revenue by Country (US$ Million), 2027–2032
Table 32. Europe Radioligand Therapy Drugs for Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 33. Europe Radioligand Therapy Drugs for Cancer Sales by Country (K Units), 2021–2026
Table 34. Europe Radioligand Therapy Drugs for Cancer Sales by Country (K Units), 2027–2032
Table 35. Europe Radioligand Therapy Drugs for Cancer Revenue by Country (US$ Million), 2021–2026
Table 36. Europe Radioligand Therapy Drugs for Cancer Revenue by Country (US$ Million), 2027–2032
Table 37. Asia Pacific Radioligand Therapy Drugs for Cancer Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 38. Asia Pacific Radioligand Therapy Drugs for Cancer Sales by Region (K Units), 2021–2026
Table 39. Asia Pacific Radioligand Therapy Drugs for Cancer Sales by Region (K Units), 2027–2032
Table 40. Asia Pacific Radioligand Therapy Drugs for Cancer Revenue by Region (US$ Million), 2021–2026
Table 41. Asia Pacific Radioligand Therapy Drugs for Cancer Revenue by Region (US$ Million), 2027–2032
Table 42. Latin America Radioligand Therapy Drugs for Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 43. Latin America Radioligand Therapy Drugs for Cancer Sales by Country (K Units), 2021–2026
Table 44. Latin America Radioligand Therapy Drugs for Cancer Sales by Country (K Units), 2027–2032
Table 45. Latin America Radioligand Therapy Drugs for Cancer Revenue by Country (US$ Million), 2021–2026
Table 46. Latin America Radioligand Therapy Drugs for Cancer Revenue by Country (US$ Million), 2027–2032
Table 47. Middle East and Africa Radioligand Therapy Drugs for Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 48. Middle East and Africa Radioligand Therapy Drugs for Cancer Sales by Country (K Units), 2021–2026
Table 49. Middle East and Africa Radioligand Therapy Drugs for Cancer Sales by Country (K Units), 2027–2032
Table 50. Middle East and Africa Radioligand Therapy Drugs for Cancer Revenue by Country (US$ Million), 2021–2026
Table 51. Middle East and Africa Radioligand Therapy Drugs for Cancer Revenue by Country (US$ Million), 2027–2032
Table 52. Global Radioligand Therapy Drugs for Cancer Sales (K Units) by Type (2021–2026)
Table 53. Global Radioligand Therapy Drugs for Cancer Sales (K Units) by Type (2027–2032)
Table 54. Global Radioligand Therapy Drugs for Cancer Sales Market Share by Type (2021–2026)
Table 55. Global Radioligand Therapy Drugs for Cancer Sales Market Share by Type (2027–2032)
Table 56. Global Radioligand Therapy Drugs for Cancer Revenue (US$ Million) by Type (2021–2026)
Table 57. Global Radioligand Therapy Drugs for Cancer Revenue (US$ Million) by Type (2027–2032)
Table 58. Global Radioligand Therapy Drugs for Cancer Revenue Market Share by Type (2021–2026)
Table 59. Global Radioligand Therapy Drugs for Cancer Revenue Market Share by Type (2027–2032)
Table 60. Global Radioligand Therapy Drugs for Cancer Price (US$/Unit) by Type (2021–2026)
Table 61. Global Radioligand Therapy Drugs for Cancer Price (US$/Unit) by Type (2027–2032)
Table 62. Global Radioligand Therapy Drugs for Cancer Sales (K Units) by Application (2021–2026)
Table 63. Global Radioligand Therapy Drugs for Cancer Sales (K Units) by Application (2027–2032)
Table 64. Global Radioligand Therapy Drugs for Cancer Sales Market Share by Application (2021–2026)
Table 65. Global Radioligand Therapy Drugs for Cancer Sales Market Share by Application (2027–2032)
Table 66. Global Radioligand Therapy Drugs for Cancer Revenue (US$ Million) by Application (2021–2026)
Table 67. Global Radioligand Therapy Drugs for Cancer Revenue (US$ Million) by Application (2027–2032)
Table 68. Global Radioligand Therapy Drugs for Cancer Revenue Market Share by Application (2021–2026)
Table 69. Global Radioligand Therapy Drugs for Cancer Revenue Market Share by Application (2027–2032)
Table 70. Global Radioligand Therapy Drugs for Cancer Price (US$/Unit) by Application (2021–2026)
Table 71. Global Radioligand Therapy Drugs for Cancer Price (US$/Unit) by Application (2027–2032)
Table 72. Novartis Company Information
Table 73. Novartis Description and Business Overview
Table 74. Novartis Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 75. Novartis Radioligand Therapy Drugs for Cancer Product
Table 76. Novartis Recent Developments/Updates
Table 77. Bayer Company Information
Table 78. Bayer Description and Business Overview
Table 79. Bayer Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 80. Bayer Radioligand Therapy Drugs for Cancer Product
Table 81. Bayer Recent Developments/Updates
Table 82. Progenics (Lantheus) Company Information
Table 83. Progenics (Lantheus) Description and Business Overview
Table 84. Progenics (Lantheus) Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 85. Progenics (Lantheus) Radioligand Therapy Drugs for Cancer Product
Table 86. Progenics (Lantheus) Recent Developments/Updates
Table 87. Acrotech Biopharma Inc Company Information
Table 88. Acrotech Biopharma Inc Description and Business Overview
Table 89. Acrotech Biopharma Inc Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 90. Acrotech Biopharma Inc Radioligand Therapy Drugs for Cancer Product
Table 91. Acrotech Biopharma Inc Recent Developments/Updates
Table 92. BMS Company Information
Table 93. BMS Description and Business Overview
Table 94. BMS Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 95. BMS Radioligand Therapy Drugs for Cancer Product
Table 96. BMS Recent Developments/Updates
Table 97. AstraZeneca Company Information
Table 98. AstraZeneca Description and Business Overview
Table 99. AstraZeneca Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 100. AstraZeneca Radioligand Therapy Drugs for Cancer Product
Table 101. AstraZeneca Recent Developments/Updates
Table 102. Eli Lilly Company Information
Table 103. Eli Lilly Description and Business Overview
Table 104. Eli Lilly Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 105. Eli Lilly Radioligand Therapy Drugs for Cancer Product
Table 106. Eli Lilly Recent Developments/Updates
Table 107. Convergent Therapeutics Company Information
Table 108. Convergent Therapeutics Description and Business Overview
Table 109. Convergent Therapeutics Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 110. Convergent Therapeutics Radioligand Therapy Drugs for Cancer Product
Table 111. Convergent Therapeutics Recent Developments/Updates
Table 112. Grand Pharmaceutical Company Information
Table 113. Grand Pharmaceutical Description and Business Overview
Table 114. Grand Pharmaceutical Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 115. Grand Pharmaceutical Radioligand Therapy Drugs for Cancer Product
Table 116. Grand Pharmaceutical Recent Developments/Updates
Table 117. Bivision Pharmaceuticals Company Information
Table 118. Bivision Pharmaceuticals Description and Business Overview
Table 119. Bivision Pharmaceuticals Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 120. Bivision Pharmaceuticals Radioligand Therapy Drugs for Cancer Product
Table 121. Bivision Pharmaceuticals Recent Developments/Updates
Table 122. Jiangsu Hengrui Company Information
Table 123. Jiangsu Hengrui Description and Business Overview
Table 124. Jiangsu Hengrui Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 125. Jiangsu Hengrui Radioligand Therapy Drugs for Cancer Product
Table 126. Jiangsu Hengrui Recent Developments/Updates
Table 127. Key Raw Materials Lists
Table 128. Raw Materials Key Suppliers Lists
Table 129. Radioligand Therapy Drugs for Cancer Distributors List
Table 130. Radioligand Therapy Drugs for Cancer Customers List
Table 131. Radioligand Therapy Drugs for Cancer Market Trends
Table 132. Radioligand Therapy Drugs for Cancer Market Drivers
Table 133. Radioligand Therapy Drugs for Cancer Market Challenges
Table 134. Radioligand Therapy Drugs for Cancer Market Restraints
Table 135. Research Programs/Design for This Report
Table 136. Key Data Information from Secondary Sources
Table 137. Key Data Information from Primary Sources
Table 138. Authors List of This Report
List of Figures
Figure 1. Product Picture of Radioligand Therapy Drugs for Cancer
Figure 2. Global Radioligand Therapy Drugs for Cancer Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Radioligand Therapy Drugs for Cancer Market Share by Type: 2025 & 2032
Figure 4. Lutetium 177 Product Picture
Figure 5. Radium 223 Product Picture
Figure 6. Acetium 225 Product Picture
Figure 7. Others Product Picture
Figure 8. Global Radioligand Therapy Drugs for Cancer Market Value by Targeted Ligands (US$ Million), 2021–2032
Figure 9. Global Radioligand Therapy Drugs for Cancer Market Share by Targeted Ligands: 2025 vs 2032
Figure 10. by Peptides Product Picture
Figure 11. Small Molecules Product Picture
Figure 12. Antibodies Product Picture
Figure 13. Others Product Picture
Figure 14. Global Radioligand Therapy Drugs for Cancer Market Value by Radionuclides (US$ Million), 2021–2032
Figure 15. Global Radioligand Therapy Drugs for Cancer Market Share by Radionuclides: 2025 vs 2032
Figure 16. β-emitters Product Picture
Figure 17. α-emitters Product Picture
Figure 18. Others Product Picture
Figure 19. Global Radioligand Therapy Drugs for Cancer Market Value by Application (US$ Million), 2021–2032
Figure 20. Global Radioligand Therapy Drugs for Cancer Market Share by Application: 2025 & 2032
Figure 21. Prostate Cancer
Figure 22. Liver Cancer
Figure 23. Breast Cancer
Figure 24. Lung Cancer
Figure 25. Others
Figure 26. Global Radioligand Therapy Drugs for Cancer Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 27. Global Radioligand Therapy Drugs for Cancer Market Size (US$ Million), 2021–2032
Figure 28. Global Radioligand Therapy Drugs for Cancer Sales (K Units), 2021–2032
Figure 29. Global Radioligand Therapy Drugs for Cancer Average Price (US$/Unit), 2021–2032
Figure 30. Radioligand Therapy Drugs for Cancer Report Years Considered
Figure 31. Radioligand Therapy Drugs for Cancer Sales Share by Manufacturers in 2025
Figure 32. Global Radioligand Therapy Drugs for Cancer Revenue Share by Manufacturers in 2025
Figure 33. Top 5 and Top 10 Global Radioligand Therapy Drugs for Cancer Players: Market Share by Revenue in Radioligand Therapy Drugs for Cancer in 2025
Figure 34. Radioligand Therapy Drugs for Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 35. Global Radioligand Therapy Drugs for Cancer Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 36. North America Radioligand Therapy Drugs for Cancer Sales Market Share by Country (2021–2032)
Figure 37. North America Radioligand Therapy Drugs for Cancer Revenue Market Share by Country (2021–2032)
Figure 38. United States Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Canada Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Europe Radioligand Therapy Drugs for Cancer Sales Market Share by Country (2021–2032)
Figure 41. Europe Radioligand Therapy Drugs for Cancer Revenue Market Share by Country (2021–2032)
Figure 42. Germany Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. France Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. U.K. Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Italy Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Russia Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Asia Pacific Radioligand Therapy Drugs for Cancer Sales Market Share by Region (2021–2032)
Figure 48. Asia Pacific Radioligand Therapy Drugs for Cancer Revenue Market Share by Region (2021–2032)
Figure 49. China Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Japan Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. South Korea Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. India Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Australia Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. China Taiwan Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Southeast Asia Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. Latin America Radioligand Therapy Drugs for Cancer Sales Market Share by Country (2021–2032)
Figure 57. Latin America Radioligand Therapy Drugs for Cancer Revenue Market Share by Country (2021–2032)
Figure 58. Mexico Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 59. Brazil Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 60. Argentina Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 61. Colombia Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 62. Middle East and Africa Radioligand Therapy Drugs for Cancer Sales Market Share by Country (2021–2032)
Figure 63. Middle East and Africa Radioligand Therapy Drugs for Cancer Revenue Market Share by Country (2021–2032)
Figure 64. Turkey Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 65. Saudi Arabia Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 66. UAE Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 67. Global Sales Market Share of Radioligand Therapy Drugs for Cancer by Type (2021–2032)
Figure 68. Global Revenue Market Share of Radioligand Therapy Drugs for Cancer by Type (2021–2032)
Figure 69. Global Radioligand Therapy Drugs for Cancer Price (US$/Unit) by Type (2021–2032)
Figure 70. Global Sales Market Share of Radioligand Therapy Drugs for Cancer by Application (2021–2032)
Figure 71. Global Revenue Market Share of Radioligand Therapy Drugs for Cancer by Application (2021–2032)
Figure 72. Global Radioligand Therapy Drugs for Cancer Price (US$/Unit) by Application (2021–2032)
Figure 73. Radioligand Therapy Drugs for Cancer Value Chain
Figure 74. Channels of Distribution (Direct Vs Distribution)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Ethylene Oxide (EO) Market Research Report 2026
Jan 17, 26
Global Stem Cells Cryopreservation Equipments Market Research Report 2026
Jan 17, 26
Global Selenium-enriched Yeast Market Research Report 2026
Jan 17, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232